» Articles » PMID: 31001253

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model

Abstract

Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft- vs.-host disease (GVHD). However, despite promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to demonstrate their superiority over placebo in the sole phase III trial reported thus far. MSCs from different tissue origins display different characteristics, but their therapeutic benefits have never been directly compared in GVHD. Here, we compared the impact of BM-, umbilical cord (UC-), and adipose-tissue (AT-) derived MSCs on T-cell function and assessed their efficacy for the treatment of GVHD induced by injection of human peripheral blood mononuclear cells in NOD-scid IL-2Rγ HLA-A2/HHD mice. , resting BM- and AT-MSCs were more potent than UC-MSCs to inhibit lymphocyte proliferation, whereas UC- and AT-MSCs induced a higher regulatory T-cell (CD4CD25FoxP3)/T helper 17 ratio. Interestingly, AT-MSCs and UC-MSCs activated the coagulation pathway at a higher level than BM-MSCs. , AT-MSC infusions were complicated by sudden death in 4 of 16 animals, precluding an analysis of their efficacy. Intravenous MSC infusions (UC- or BM- combined) failed to significantly increase overall survival (OS) in an analysis combining data from 80 mice (hazard ratio [HR] = 0.59, 95% confidence interval [CI] 0.32-1.08, = 0.087). In a sensitivity analysis we also compared OS in control vs. each MSC group separately. The results for the BM-MSC vs. control comparison was HR = 0.63 (95% CI 0.30-1.34, = 0.24) while the figures for the UC-MSC vs. control comparison was HR = 0.56 (95% CI 0.28-1.10, = 0.09). Altogether, these results suggest that MSCs from various origins have different effects on immune cells and . However, none significantly prevented death from GVHD. Finally, our data suggest that the safety profile of AT-MSC and UC-MSC need to be closely monitored given their pro-coagulant activities .

Citing Articles

Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.

Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S Stem Cell Res Ther. 2024; 15(1):461.

PMID: 39627816 PMC: 11613890. DOI: 10.1186/s13287-024-04064-w.


Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial.

Jiang E, Qian K, Wang L, Yang D, Shao Y, Hu L BMC Med. 2024; 22(1):555.

PMID: 39587570 PMC: 11590523. DOI: 10.1186/s12916-024-03782-5.


Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice.

Ehx G, Ritacco C, Baron F Biomark Res. 2024; 12(1):139.

PMID: 39543777 PMC: 11566168. DOI: 10.1186/s40364-024-00684-9.


Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.

Yang P, Zhao X, Kou Y, Liu J, Ren X, Zhang Y Acta Pharmacol Sin. 2024; 45(11):2339-2353.

PMID: 38802569 PMC: 11489431. DOI: 10.1038/s41401-024-01283-y.


Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19.

Hou X, Danzeng L, Wu Y, Ma Q, Yu Z, Li M World J Stem Cells. 2024; 16(4):353-374.

PMID: 38690515 PMC: 11056634. DOI: 10.4252/wjsc.v16.i4.353.


References
1.
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363(9419):1439-41. DOI: 10.1016/S0140-6736(04)16104-7. View

2.
Bleakley M, Riddell S . Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004; 4(5):371-80. DOI: 10.1038/nrc1365. View

3.
Reddy M, Eirikis E, Davis C, Davis H, Prabhakar U . Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004; 293(1-2):127-42. DOI: 10.1016/j.jim.2004.07.006. View

4.
Baron F, Storb R . Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol. 2004; 26(1-2):71-94. DOI: 10.1007/s00281-004-0165-3. View

5.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View